Get the app Watchlists Portfolios Alerts Sign in Get started

Menu

Innate Pharma S.A. IPHA

Full chart Compare

Set alert

1.40 USD -0.03 (-1.75%)

At closeNov 5, 2026, 4:00 PM EST

1.46 +0.06 +4.29%

After hours · Nov 5, 4:00 PM ET

1.38 Day range 1.41

1.17 52-week range 2.71

YTD: -20.00%
1 year: -23.08%

News

20 hours ago marketbeat.com Innate Pharma Q3 Earnings Call Highlights Innate Pharma NASDAQ: IPHA said it has initiated a Phase 3 study of its lymphoma drug lacutamab and expects to present Phase 1 data for its experimental cancer treatment IPH4502 on Nov. 18, as the…
1 day ago benzinga.com Innate Pharma 9M Revenue €3.4M Vs €2.3M YoY, Cash €96.8M; CFO Frédéric Lombard To Step Down December 31 Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person eventLacutamab, partnered with Sobi, progressing toward first…